A scientific, health-economic analysis of why multinationals stall MedTech disruption—and how regulation, reimbursement, and system reform can rebuild an innovation engine.

Medical devices shaped every major advance in modern medicine—from coronary stents and EVAR to robotic surgery, electrophysiology, and rapid molecular diagnostics. Yet despite extraordinary technical capability, the rate of genuinely disruptive innovation in MedTech is slowing.

This slowdown is not a matter of opinion. It is documented repeatedly across health-economic evaluations, regulatory studies, post-market surveillance analyses, and organisational research. Over the past decade, multinationals, regulators, HTA bodies, and hospital procurement systems have—often unintentionally—constructed an ecosystem that punishes disruption, rewards incrementalism, and structurally inhibits clinician-led innovation.

The result is an industry optimised for small, reimbursable product iterations rather than transformative technologies. Regulatory complexity, reimbursement structures, IP behaviour, cybersecurity constraints, and market concentration reinforce each other, creating an environment where breakthrough ideas die early and late-stage “safe” innovation becomes the norm.

This article synthesises scientific evidence from open-access academic and health-economic research to examine why multinationals stall disruption—and how regulation, reimbursement design, procurement reform, and policy innovation can rebuild a functioning, distributed innovation engine capable of producing real clinical impact.

The Innovation Myth Why MedTech Doesn’t Behave Like Pharma

Medical device innovation is fundamentally different from pharmaceutical innovation.
While drugs emerge from centralised industrial R&D programmes with long regulatory pathways and controlled pipelines, the most transformative medical devices originate at the bedside, not in corporate laboratories.

Unlike pharmaceuticals—where discovery is driven by molecular science and industrial screening—MedTech breakthroughs emerge from clinical intuition, tacit knowledge, and real-world problem-solving. They are born in operating theatres, cath labs, emergency departments, and intervention suites, where clinicians confront technical limitations and invent practical solutions under pressure.

This is why MedTech does not follow pharma’s innovation logic, investment structures, or translational science pathways.

Clinician-Innovators Drive Transformative Breakthroughs

Evidence from Kesselheim, Avorn, and colleagues (PLoS One; open-access), supported by ethnographic and health-innovation literature, demonstrates that many landmark devices were conceived by clinicians themselves, including:

Coronary stents
Endovascular aneurysm repair (EVAR)
Endovascular graft systems
Minimally invasive and laparoscopic surgery techniques
Neurovascular thrombectomy and clot-retrieval systems
Heart valves and structural interventions (TAVI precursors)

These inventions were not the product of long-term corporate R&D planning.
They were created by:

iterating prototypes at the bedside
improvising with available tools
applying engineering principles during procedures
combining disciplines (vascular surgery + radiology + engineering)
designing fixes in response to life-threatening complications

In innovation theory, this is experience-driven, tacit-knowledge innovation — something that cannot be replicated in a conference room or R&D department.

It is also a form of situated cognition, where solutions arise from the immediate environment and procedural constraints.

This is what makes clinician-led MedTech innovation uniquely powerful.

And uniquely vulnerable.

Why This Matters — The Innovation Pipeline Collapses at Its Source

If clinicians are the true innovators, but the ecosystem systematically obstructs clinician-led invention, then the entire MedTech innovation pipeline collapses upstream, before ideas even reach feasibility.

From a scientific standpoint:

Regulatory science now requires high-grade evidence far earlier than feasible for clinician-inventors.
Health-technology assessment (HTA) demands cost-effectiveness modelling before any adoption occurs.
Reimbursement systems reward only predictable, established product categories.
Corporate governance prioritises incrementalism and predictable returns.
Procurement frameworks favour incumbents and penalise unfamiliar technologies.

This constellation of forces creates an environment where:

disruptive prototypes never leave the clinical setting
early innovations die before design freeze
ideas remain undocumented or unpublished
surgeons stop experimenting
interventionalists lose autonomy
innovators exit the field entirely

In health-economic terms, the system exhibits a negative innovation gradient:
the further upstream an idea emerges, the less likely it is to survive.

This is the core of the MedTech innovation paradox:

The people best placed to solve clinical problems are the least supported by the current innovation ecosystem.
The people with the resources to commercialise innovations are the least exposed to clinical problems.

Until this misalignment is corrected, disruptive MedTech innovation will continue to slow—regardless of technological capability.

The Economics of Stagnation — Why Multinationals Prefer Incrementalism

Health-economic research consistently demonstrates a structural truth about the medical device industry:
incremental innovation maximises financial return and minimises risk, whereas disruptive innovation amplifies cost, regulatory uncertainty, and strategic exposure.

Unlike pharmaceuticals — where blockbuster breakthroughs can produce multi-decade revenue streams — MedTech is constrained by reimbursement structures, procedural codes, and product life cycles that inherently favour small, predictable upgrades over paradigm shifts.

This economic configuration drives the core behaviour of multinational device companies and explains why disruptive innovation struggles to survive.

Shareholder Pressure Shapes Corporate Innovation Strategy

Multinational MedTech companies operate under intense financial expectations from:

public markets
institutional investors
private equity ownership
strategic analysts
internal performance metrics

These stakeholders expect:

quarterly revenue growth
stable gross margins
predictable product-refresh cycles
low-variance profitability
regulatory and reimbursement certainty

From a health-economic standpoint, innovation strategy is therefore governed by risk-adjusted ROI, not clinical ambition or scientific novelty.

Why incrementalism becomes rational strategy

Incremental upgrades—new coatings, minor design changes, next-generation delivery systems—provide:

rapid regulatory approval (via 510(k) pathways or CE variations)
existing reimbursement eligibility (no need to create new DRG, CCAM, OPCS, CPT, NABM, LPPR codes)
low training burden (hospitals adopt upgrades without workflow disruption)
guaranteed sales into established customer bases
high margins with minimal redesign cost

In economic terms:

Low uncertainty → low capital cost → high predictability → maximised shareholder value

This is why major device companies behave more like portfolio-optimisation systems than innovation engines.

The Economic Penalty for Disruption

True disruption imposes structural frictions at every point in the MedTech value chain.

Academic evidence (e.g., Maresova et al., 2020, Administrative Sciences) shows that the risk profile of disruptive innovation is disproportionately high due to the following cost drivers:

1. Reimbursement barriers

A disruptive device often does not fit existing reimbursement categories, requiring:

entirely new DRG or tariff creation
new procedure codes (OPS, CCAM, CPT, OPCS-4)
national pricing negotiations (CEPS, CMS, InEK)
economic modelling for HTA bodies

This process takes years and is inherently uncertain.

2. Organisational and workflow disruption

Disruptive devices usually require:

new clinical pathways
integration with digital systems
perioperative retraining
modifications to hospital logistics
changes in risk governance

Hospitals resist technologies that impose operational friction.

3. Regulatory uncertainty

Breakthrough technologies must generate:

early clinical data
post-market surveillance (PMCF)
usability evidence (IEC 62366)
safety validation (ISO 14971)

Regulators must scrutinise novel mechanisms more intensely than incremental ones, increasing delays and costs.

4. Evidence-generation burden

HTA bodies (HAS, NICE, G-BA, RedETS) require:

comparative effectiveness data
health-economic modelling
RWE
long-term outcome evidence

Small innovators cannot afford such studies; corporates are reluctant to finance them without guaranteed reimbursement.

5. Cannibalisation of existing product lines

This is a rarely spoken but scientifically documented reality.
Disruptive technologies threaten:

established SKUs
high-margin consumables
long-standing procurement contracts
existing revenue channels

Therefore, internal corporate incentives often suppress innovations that would erode current cashflows.

The Economic Logic Becomes Self-Reinforcing

As a result, the industry evolves towards systemic incrementalism:

predictable revenue is privileged over clinical transformation
risk is offloaded onto start-ups and academia
acquisitions replace research
breakthrough ideas die before commercialisation
market concentration increases
innovation velocity falls

This feedback loop is what economists describe as a negative innovation elasticity:
the larger and more dominant a company becomes, the less incentive it has to disrupt itself.

Maresova et al. (2020) captured this dynamic precisely:

“Large MedTech companies optimise for risk minimisation, not scientific ambition.”

This is not a cultural failure — it is a mathematical outcome of the current economic architecture.

Regulatory Chokepoints Freezing Innovation

Across the EU, the UK, and the U.S., regulatory evolution has created a systemic innovation bottleneck.
These barriers were not designed to suppress new technologies—they emerged from legitimate goals: improving patient safety, strengthening post-market surveillance, mitigating device failures, and harmonising quality standards.

Yet the cumulative effect of these regulatory frameworks is now scientifically measurable:
they disproportionately increase the cost, complexity, and uncertainty of disruptive MedTech innovation, while structurally favouring large multinationals and incremental device updates.

This phenomenon is now well-documented in regulatory science, industrial organisation, and health-economic literature.

EU MDR — A Well-Intentioned Reform That Overcorrected

Regulatory science evidence

Peer-reviewed analyses (e.g., Maresova et al., 2020; Team-NB surveys; EC Notified Bodies Study) demonstrate that the Medical Device Regulation (EU MDR 2017/745):

increased certification costs by 300–400% for some device classes
lengthened approval timelines by 2–3×
reduced the number of operational Notified Bodies
created large approval backlogs (12–24+ months)
shifted the regulatory burden toward SMEs while advantaging large firms

Innovation effects

From an economic standpoint, MDR converts innovation into a capital-intensive, high-friction activity, producing:

fewer early-stage entrants
withdrawal of niche but clinically valuable devices
consolidation of product portfolios
increased market concentration**
reduced ability of clinicians to test prototypes under controlled conditions

In innovation theory terms, MDR has produced a “regulatory drag coefficient” — a measurable friction applied uniformly across all devices, regardless of risk or novelty.

Why multinationals benefit

Large corporations absorb MDR obligations through:

existing quality systems
global regulatory teams
diversified revenue streams
legal resources
large-scale PMCF infrastructure

SMEs cannot.
Thus, MDR unintentionally selects for scale over creativity.

FDA Pathways — A Structural Bias Toward Incrementalism

FDA’s device approval ecosystem consists primarily of:

510(k) clearance (substantial equivalence)
De Novo classification
PMA (Premarket Approval)

The problem: 510(k) dominates

Over 90% of new devices enter the U.S. market through the 510(k) pathway, which allows companies to demonstrate “equivalence” to an existing predicate.

Regulatory science evidence (Horvath, 2024; Zuckerman et al., JAMA) shows:

510(k) inherently favours incremental modifications
disruptive technologies often do not qualify
predicate reliance creates a “technology lineage lock-in”
early-stage innovators cannot demonstrate equivalence
high-risk innovations require PMA → slow, expensive, unpredictable

The result: incremental devices thrive, while disruptive ones face steep barriers.

Health Technology Assessment (HTA) Increases Evidence Thresholds

Modern HTA agencies (NICE, HAS, G-BA, RedETS, AGENAS, CADTH) demand comprehensive evidence packages before national reimbursement, including:

comparative effectiveness
real-world evidence (RWE)
organisational impact modelling
budget impact analysis
cost-effectiveness modelling (CEA/CUA)
usability and human factors evidence
long-term outcomes
safety surveillance integration

This is a scientifically rational process, but it creates an innovation timing paradox:

To obtain reimbursement → you need large-scale evidence

To generate evidence → you need reimbursement or adoption

To gain adoption → hospitals need reimbursement in place

This is the RWE–Reimbursement Deadlock, a documented market failure in MedTech.

Startups cannot cross this evidence threshold without early clinical deployment.
Multinationals often avoid disruptive products because HTA requirements reduce ROI predictability.

Post-Market Surveillance (PMS/PMCF) Adds Perpetual Obligations

Under MDR and evolving FDA requirements, devices require:

PMCF studies
registry participation
long-term safety tracking
device traceability
UDI compliance with EUDAMED
periodic safety update reports

Zippel & Bohnet-Joschko (2017) highlight that PMS obligations are now so extensive that post-market evidence costs exceed pre-market costs in many device categories.

Why this matters for innovation

Disruptive devices require more intensive post-market scrutiny.
This produces:

higher operating expenses
resource allocation away from new innovation
reduction in R&D pipeline diversity

Regulatory Convergence Creates Cumulative Burden

The EU, UK, and U.S. are gradually converging towards:

lifecycle evidence frameworks
AI transparency requirements
more rigorous software validation
cybersecurity testing
RWE integration
ethical and human-factor design standards

While scientifically defensible, this convergence produces a compound burden for innovators who must meet:

MDR
UKCA
FDA
HTA
GDPR / HIPAA
clinical safety standards
cybersecurity certification
ISO 13485, 14971, 62304, 62366-1
DCB0129/0160 in the UK

Individually justified.
Collectively overwhelming.

Why This Freezes Disruption

When regulatory science, HTA requirements, and post-market obligations intersect, they create:

long timelines
unpredictable outcomes
capital-intensive development cycles
regulatory sequencing risks
increased cost of failure
reduced appetite for high-risk R&D

This produces a regulatory innovation gradient:

The more novel the technology, the harder the regulatory pathway, the greater the economic risk, and the lower the probability of commercial survival.

Incremental devices glide through the system.
Breakthroughs stall.

MDR has increased regulatory cost by 300–400%

Key findings from open-access regulatory analyses:

CE marking timelines have doubled or tripled
Notified Body shortages delay approval 12–24 months
PMCF requirements impose heavy long-term cost
Small innovators exit markets due to compliance costs

(Reference: Maresova et al., 2020 — Administrative Sciences)
https://www.mdpi.com/2076-3387/10/1/16

Impact on innovators

SMEs cannot survive multi-year certification cycles.
Multinationals can.
Thus: regulation accelerates market consolidation.

FDA’s 510(k) fosters incremental innovation

Horvath (2024, SSRN) shows that >90% of U.S. device approvals use the 510(k) predicate pathway, which fundamentally:

Favours incremental devices
Disincentivises disruptive redesign
Protects legacy technologies

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4824122

HTA bodies demand evidence innovators cannot produce

Across NICE, HAS, G-BA, RedETS, AGENAS:

RWE
full economic models
organisational impact
usability evidence
learning-curve analyses

are required before adoption occurs.

This creates a structural paradox:

To get reimbursement → need evidence
To get evidence → need adoption
To get adoption → need reimbursement

This is the RWE–Reimbursement Death Spiral.

Clinicians Can No Longer Innovate — The Collapse of Frontline Creativity

Across Europe, the UK, the U.S., and global health systems, the structural capacity of clinicians to innovate has deteriorated sharply.
Open-access research (Jarosławski & Saberwal, 2013; Courvoisier, 2016) shows that historically, clinician-led invention was the primary source of MedTech breakthroughs.
Today, however, the frontline environments that once nurtured creativity have become inhospitable to innovation.

A combination of workload pressure, procurement barriers, legal constraints, and corporate behaviours has created a system in which clinicians are no longer positioned—or permitted—to invent, iterate, or experiment.

This is not a cultural shift.
It is a structural failure.

H3: 4.1 The Loss of Protected Creative Time

Clinical innovation requires cognitive space, autonomy, and the ability to explore alternative techniques.
Modern clinical environments systematically eliminate these conditions.

Evidence shows that clinicians now face:

rising patient volumes with increasing acuity
administrative overload driven by coding, documentation, and compliance
fear of litigation discouraging procedural exploration
protocolised, algorithm-driven pathways that limit deviation
productivity and throughput metrics that penalise experimentation

In organisational psychology, innovation requires slack resources, but frontline clinicians now operate with negative slack — meaning all available capacity is consumed by mandatory tasks.

This creates what health-innovation researchers describe as innovation starvation:
no time to invent, no space to prototype, no institutional air to breathe.

Disruptive ideas disappear long before they can be articulated, tested, or shared.

H3: 4.2 Procurement Systems That Block Disruptive Devices

Procurement systems—while rational from a cost-control perspective—are structurally hostile to early-stage innovation.

Hospitals increasingly operate through:

framework agreements with fixed suppliers
bulk purchasing contracts that favour scale over novelty
tender specifications written by incumbent manufacturers
lowest-price technical tendering (LPTA) that undervalues innovation
multi-year supplier lock-in arrangements
risk-averse purchasing committees lacking clinical innovators

This creates Procurement Lock-In, where:

novel devices cannot enter competitions
disruptive technologies are excluded by design
tenders reinforce existing product ecosystems
startups lack the certifications or safety data demanded at tender stage
clinicians cannot trial early prototypes without violating purchasing rules

Procurement becomes a mechanism of technological inertia, ensuring that markets reward established vendors and penalise new entrants.

This is a critical but overlooked driver of MedTech stagnation.

H3: 4.3 Corporate Threats, Legal Pressure, and Suppression of Clinical Creativity

A growing body of evidence documents a concerning trend:
corporate legal teams increasingly intervene to suppress clinician-led innovation, particularly when novel techniques threaten existing product lines.

Case studies show clinicians receiving:

cease-and-desist letters
warnings about procedural deviations
intellectual property disputes
claims of patent infringement for publishing alternative methods
legal intimidation discouraging further exploration
pressures from corporate-aligned advisors

Van Haute (2011) and subsequent reports in vascular and orthopaedic surgery highlight that multinational manufacturers actively monitor social media, conferences, and publications for “unauthorised innovation.”

This has a chilling effect:

clinicians self-censor
novel procedural approaches remain unpublished
interdisciplinary experimentation declines
mentors discourage trainees from innovating
litigation fear overrides creativity

The message sent to clinicians is clear:
If your idea threatens a corporate product, it is safer not to pursue it.

H3: 4.4 Corporate Employment Pathways Suppress Creativity

Innovation flourishes when individuals have:

autonomy
empowerment
the ability to deviate from norms
hands-on access to prototypes
interdisciplinary collaboration

Large healthcare corporations increasingly eliminate these conditions.

Organisational science shows that:

hierarchical structures suppress divergent thinking
compliance frameworks restrict experimentation
risk-aversion becomes cultural
internal review processes slow iteration
innovation budgets are centralised and politically contested

Furthermore, as Xiao (2022) demonstrates, non-compete agreements and IP assignment clauses now effectively:

prevent clinician–engineer collaboration
restrict movement of creative individuals
prevent knowledge flow between hospitals and startups
give corporations control over clinician-generated ideas

The result is a closed innovation system, where clinicians can participate—but only under strict corporate terms.

This is the opposite of the open, iterative, clinically grounded innovation environment that produced the greatest device breakthroughs of the 20th century.

Why This Matters — The Innovation Pipeline Fails at Its Origin

Clinicians were historically the origin point of transformative devices.
If they lose:

time
autonomy
legal protection
procurement access
institutional support
collaborative freedom

—then the innovation pipeline collapses at its earliest stage.

In health-economic terms, this produces:

a decline in grassroots prototype generation
fewer early clinical observations being translated into designs
increased dependence on corporate R&D
reduced diversity of device concepts
slower innovation velocity
higher system inertia

This is why the system cannot generate disruptive MedTech at scale:
the people who invent cannot innovate; the people who can innovate are not inventors.

The Corporate Immune System — Why Large Organisations Kill Disruption

Innovation scholars describe a universal phenomenon across industries:
as organisations grow, they develop an “immune system” that instinctively detects, resists, and neutralises disruptive ideas.

In MedTech, this phenomenon is amplified by regulatory frameworks, reimbursement structures, liability constraints, and entrenched product lines.
The result is a behavioural and economic system that protects the status quo, even when doing so undermines clinical progress.

This “corporate immune system” is not intentional sabotage.
It is the predictable psychological and structural response of large organisations facing uncertainty.

MedTech therefore faces an innovation paradox grounded in:

organisational psychology
behavioural economics
cognitive bias
regulatory burden
financial risk
legal exposure
cultural conservatism

Below, we break down the science.

Organisational Psychology: Why Large Firms Fear Disruptive Ideas

Organisational Defence Mechanisms (ODM)

According to organisational psychology, large corporations develop defence mechanisms similar to biological immune systems:

detect deviations
isolate uncertainty
eliminate threats to stability
prioritise predictability

These mechanisms manifest as:

rejection of unfamiliar ideas
scepticism toward early prototypes
bureaucratic delay
aggressive risk management
legal suppression of novel techniques

This is driven by structural homeostasis: organisations seek equilibrium, not disruption.

Behavioural Economics: Loss Aversion

Kahneman and Tversky’s research shows that organisations are twice as sensitive to potential losses as to equivalent gains.

For multinationals, disruptive innovation introduces:

uncertain ROI
regulatory delays
reimbursement ambiguity
litigation risk

Thus, not innovating feels safer than innovating.

Groupthink & Conformity Pressures

Large companies have:

shared narratives
internal political incentives
hierarchical decision-making
committees that default to consensus

This produces conformity pressure, where safe, incremental ideas survive and disruptive ones die.

Innovation psychologists call this the “conformity cascade”: good ideas vanish because no one wants to back something controversial.

Defensive IP, Legal Aggression, and Innovation Suppression

The corporate immune system also manifests through legal and IP behaviour.

Defensive Use of Intellectual Property

Multinationals often:

build vast patent walls
use IP as a deterrent
file blocking patents
threaten clinicians exploring alternative approaches
challenge procedural innovations that bypass expensive consumables

This behaviour is documented in Van Haute (2011) and multiple case studies in vascular and orthopaedic surgery.

It is rational from a corporate standpoint:
IP protects revenue streams.

But it is disastrous for innovation ecosystems.

Cease-and-Desist as a Control Strategy

Increasing evidence shows clinicians receiving:

cease-and-desist letters for publishing novel techniques
warnings for “unauthorised modifications” to devices
legal threats for sharing cost-saving alternatives

Psychologically, this induces chilling effects:

deters future idea-sharing
suppresses procedural evolution
makes innovators self-censor
reduces scientific openness

The Psychology of Control

Legal departments act as “hypervigilant agents” inside the corporate immune system.

They are primed to:

avoid liability
minimise regulatory exposure
prevent reputational risk
protect existing product dominance

These agents usually operate without understanding innovation psychology, reinforcing suppressive behaviour.

The Risk Algorithms: How Financial Structures Kill Creativity

In health-economic terms, large corporations use risk algorithms that automatically penalise ideas with:

low regulatory predictability
unclear reimbursement pathways
uncertain sales ramp
long evidence timelines
potential cannibalisation of existing products

Cannibalisation Fear (Clayton Christensen’s Innovator’s Dilemma)

If a disruptive device threatens an existing revenue stream:

the idea is deprioritised
the team loses internal political capital
budgets shift to “safer” iterations

This is cognitive dissonance at scale:
corporations intellectually value innovation but emotionally fear it.

Capital Allocation Bias

Corporate finance frameworks reward:

predictable projects
incremental upgrades
short payback periods
stable revenue lines

Disruptive innovation scores poorly in all these metrics.

From a behavioural economics lens, this is ambiguity aversion:
large firms avoid situations with uncertain probabilities.

Bureaucratic Burden & Procedural Inertia

The Psychology of Bureaucracy

Bureaucracies create psychological distance from risk.
People become process-driven, not purpose-driven.

This produces:

procedural paralysis
endless review loops
risk-avoidant committees
innovation fatigue
internal veto points

In behavioural science, this is called diffusion of responsibility:
when risk is spread across many individuals, no one wants to take the leap.

Regulatory Overcorrection

Regulation amplifies bureaucracy:

MDR
PMCF
PMS
FDA predicate reliance
quality-system documentation
cybersecurity audits
data governance compliance

Every new rule adds friction—and friction kills early-stage ideas.

Regulatory load disproportionately punishes unproven, concept-stage innovation because:

prototypes cannot yet satisfy documentation requirements
evidence is expensive
workflows are undefined
risk management is impossible without clinical data

Non-Competes, Talent Containment, and the Psychology of Skill Lock-In

Research by Xiao (2022) shows that non-compete clauses and IP assignment policies:

prevent clinicians or engineers from leaving to innovate
stop cross-pollination of ideas
make staff fear entrepreneurship
centralise control within corporations

From a psychological standpoint, non-competes create learned helplessness:
people stop imagining alternatives because they feel constrained.

This kills:

grassroots creativity
interdisciplinary collaboration
bottom-up idea flow
clinician–startup partnerships

Why This Matters — The Corporate Immune System Becomes a Public-Health Problem

When the corporate immune system becomes too powerful, the consequences extend far beyond organisational culture.

Clinical harm pathway:

Disruptive ideas die →
Evidence never develops →
Technologies never reach HTA →
Reimbursement structures remain fixed →
Hospitals never adopt new devices →
Patients receive older, less effective technology

This is no longer a business issue.
It is a public-health failure cascade.

Innovation becomes impossible—not because of a lack of ideas, but because the system systematically kills them.

Market Concentration — The Innovation Winter

Market-structure research across Europe, the UK, and the U.S. reveals a stark reality:
the medical device sector has entered a period economists describe as an Innovation Winter—a structural downturn in breakthrough innovation caused by extreme market concentration.

This is not an abstract claim.
It is a well-documented pattern across OECD market studies, industrial-organisation economics, and open-access MedTech research (Maresova et al., 2015; Bergsland et al., 2014).

How Concentrated Is the MedTech Industry?

The global picture

The top 10 device manufacturers control over 60% of worldwide market revenue.
In specific categories, concentration is dramatically higher:
- Orthopaedics: >80% controlled by four companies
- Cardiovascular stents and structural heart: >75% controlled by three companies
- Imaging and radiology: >85% dominated by two global players
- Diagnostics (IVD): >70% controlled by a handful of multinationals

This is one of the highest concentration ratios of any health-technology industry.

What this means in economic theory

According to industrial-organisation science:

The more concentrated a market becomes, the lower its innovation output.

This is a consistent empirical relationship documented across multiple research domains.

Why Market Concentration Reduces Innovation — The Economic Mechanism

1. Reduced Competitive Pressure

When only a small number of companies dominate a sector, economic incentives shift from innovation to market preservation:

protect existing product lines
maximise margins
lobby for regulatory barriers
maintain volume-based procurement contracts

Innovation stops being a competitive necessity.

2. Innovation Becomes a Threat, Not an Opportunity

Economists refer to this as cannibalisation risk.
A breakthrough product may undermine:

existing consumable revenue
multi-year procurement arrangements
legacy device ecosystems
high-margin delivery systems

Thus, dominant firms prefer:

Incremental upgrades → predictable profits
over
Disruptive technologies → unpredictable cost + regulatory risk + cannibalisation

The “Acquisition Trap”

Large medtech companies increasingly rely on acquisition instead of invention:

startups generate early concepts
multinationals acquire them
disruptive products are shelved or “strategically deprioritised”
intellectual property is absorbed to protect the incumbents

This phenomenon is well-documented in the Maresova et al. (2015) study.

Declining R&D Intensity

Open-access financial analyses show that as MedTech companies scale, R&D expenditure as a proportion of revenue decreases.
This is the reverse of what occurs in biopharmaceuticals, where large-size correlates with more R&D activity.

In MedTech:

Big = Safe
Safe = Incremental

Cost of Capital Advantages Suppress Competitors

Multinationals have:

lower borrowing costs
higher liquidity
preferential procurement status
established regulatory teams

This creates a barrier to entry for smaller innovators.

As SMEs exit due to MDR, HTA barriers, and capital constraints, the ecosystem loses the very actors responsible for disruptive invention.

The Psychological Component — How Dominant Firms Think

1. Cognitive Entrenchment

Behavioural science shows that the more successful an organisation becomes, the more its thinking ossifies.
This is called cognitive entrenchment:
dominant firms become convinced their current way is the best way.

2. Status Quo Bias

Large MedTech firms exhibit extreme status quo bias, preferring:

predictable regulatory pathways
familiar device designs
established training protocols
incremental updates over conceptual redesign

3. Fear of Disruption

Market leaders develop defensive thinking patterns:

“If it’s not broken, don’t fix it”
“New technology means new risks”
“Regulators will challenge this”
“Hospitals won’t adopt it without reimbursement”

This produces institutional conservatism.

The Consequences — The Innovation Winter

This convergence of economic and psychological forces results in measurable outcomes:

1. R&D Intensity Declines

Companies shift from invention to portfolio optimisation.

2. Risk-Taking Collapses

High-risk projects lose internal funding before feasibility studies begin.

3. Acquisition Replaces Invention

Corporations wait for startups to mature, then acquire them—often absorbing IP rather than commercialising it.

4. Prices Increase

With few competitors, costs rise globally—especially in orthopaedics, cardiovascular devices, and imaging systems.

5. SMEs Exit the Market

MDR, procurement barriers, and regulatory cost force smaller innovators out—removing the ecosystem’s creative engine.

6. Diversity of Ideas Shrinks

Fewer companies → fewer research paradigms → fewer alternative designs → stagnation.

This is the Innovation Winter gripping MedTech today:
a systemic contraction in breakthrough device development driven by concentration, risk-aversion, and structural inertia.

Why This Threatens Global Health Outcomes

Market concentration is not simply an economic or industrial trend; it is a global public-health problem.

Clinical impact pathway:

Fewer disruptive devices →
Slower adoption of safer, more effective technologies →
Reduced clinical options for complex diseases →
Higher complication rates →
Increased lifetime healthcare costs →
Avoidable morbidity and mortality

Innovation is not “nice to have.”
It is part of the essential infrastructure of modern medicine.

When concentration freezes innovation, patients pay the price.

Big Data, AI, and Cybersecurity — The New Invisible Barriers to MedTech Innovation

Although regulatory burdens and market concentration have long been recognised as major obstacles to disruptive medical device development, a newer and more insidious class of innovation barriers has emerged in parallel with the digital transformation of healthcare. These constraints—rooted in data governance, artificial intelligence regulation, cybersecurity obligations, and hospital IT architecture—form an invisible lattice of friction that disproportionately affects precisely those technologies that promise the greatest clinical value.

Paradoxically, the very domains that enable modern innovation—real-world evidence, algorithmic decision support, continuous monitoring, cloud connectivity, and personalised care—are also the domains in which regulatory expectations, compliance burdens, and institutional conservatism have escalated most dramatically. As a result, digital and connected medical devices face structural resistance long before they reach clinical evaluation, not because they lack clinical merit, but because the surrounding digital and legal infrastructure remains unprepared to absorb them.

The AI Bottleneck — When Innovation Meets Ambiguous Standards

Artificial intelligence–enabled devices, software as a medical device (SaMD), and algorithmic diagnostics face a unique constellation of scientific and regulatory challenges. While the potential for improving diagnostic accuracy, triage efficiency, and patient safety is substantial, the regulatory requirements governing transparency, generalisability, bias mitigation, model drift monitoring, and dataset provenance impose a level of evidentiary scrutiny that early-stage innovators often cannot satisfy.

Open-access research (Vollmer et al., BMJ, 2020) highlights twenty critical questions relating to transparency, replicability, ethical design, and real-world performance that AI developers must address. These include the need to document training datasets, justify algorithm behaviour, demonstrate resilience to population-level heterogeneity, and provide evidence that performance does not deteriorate over time. While scientifically justified, these requirements render early prototyping extraordinarily difficult, especially for SME-led AI solutions that lack access to high-quality, labelled datasets.

In practical terms, AI innovations stall because hospitals cannot share data, developers cannot train models, regulators cannot approve opaque systems, and HTA bodies cannot evaluate cost-effectiveness without robust external validation. This creates a self-reinforcing loop in which AI devices require evidence that can only be generated at scale, yet scale cannot be achieved without regulatory approval and adoption—a circular dependency that mirrors the RWE–Reimbursement paradox but is even more acute in digital health.

Cybersecurity and Data Governance — The High-Friction Landscape of Connected Devices

Connected devices, cloud-based monitoring systems, digital therapeutics, and remote physiological sensors must now navigate a dense network of cybersecurity, privacy, and interoperability obligations. Requirements emerging from GDPR, HIPAA, NIS2, Cybersecurity Act certifications, IEC 81001-5-1, and hospital-specific security policies impose a multi-layer compliance burden that large corporations can manage but that early innovators cannot afford.

Hospitals, acting understandably in the interest of protecting patient data and operational safety, often prohibit the deployment of external servers, block outbound API calls, restrict the installation of third-party software, and require extensive penetration testing before even a small-scale pilot can proceed. This results in an environment where new digital technologies are not evaluated primarily on clinical merit but on the institution’s cyber-risk tolerance, which is typically low due to ransomware incidents, legacy systems, and fear of IT failure.

Price & Cohen (2019, Nature Medicine) document how the “age of medical big data” has generated unprecedented tension between innovation and privacy legislation. Health data—particularly imaging, genomics, physiological waveforms, and continuous monitoring outputs—has become both the most valuable raw material for AI innovation and the most tightly regulated asset in healthcare. Consequently, the availability of training data is severely constrained, and early innovators struggle to obtain even de-identified datasets due to legal ambiguity, risk-aversion, and information governance bottlenecks.

This has profound consequences: devices designed to produce early detection, enable personalised therapies, or automate high-risk clinical workflows cannot develop because compliance requirements outpace the capacity of small firms, trials cannot begin, and scientific evaluation is rendered impossible.

Interoperability Failures and IT Architecture — When Hospitals Cannot Absorb Innovation

Even when regulatory and cybersecurity barriers are overcome, a far deeper structural barrier remains: hospital IT infrastructure is often incapable of absorbing modern connected devices, regardless of clinical value.

In the majority of health systems, digital architecture is fragmented across multiple electronic health record vendors, proprietary interfaces, legacy PACS systems, outdated HL7 implementations, and custom-built middleware. Interoperability standards such as FHIR are often partially implemented or inconsistently adopted, and hospital IT teams—working with tight budgets and constrained staffing—lack the capacity to integrate novel devices that require bi-directional data exchange.

This results in “integration inertia”: innovative devices cannot be deployed because they cannot “plug into” existing systems. Even simple workflows such as pushing a diagnostic output from a device into an EHR field, or retrieving patient metadata in real time, require weeks or months of negotiation between vendors, IT teams, security leads, and clinical governance committees.

The scientific consequence is that many promising device ideas die not because the technology fails, but because the system cannot accommodate its existence.

Digital Regulation, Ethical AI, and the Expanding Compliance Universe

The compliance landscape for digital and connected devices is not only large—it is continuously expanding. Emerging frameworks such as:

the EU AI Act
FDA’s “Good Machine Learning Practice” principles
IEC 62304 / IEC 82304-1 software safety requirements
ISO/IEC 27001 & 27701 for data security and privacy
NHS DTAC (UK)
HAS cybersecurity guidance (France)
FDA draft guidance on AI/ML-enabled SaMD
European Health Data Space (EHDS) provisions

collectively impose a moving target of regulatory expectations.

Large corporations can amortise this cost across entire product portfolios; small innovators cannot. As compliance expands faster than available resources, a form of digital regulatory inflation occurs—each year increasing the cost of doing business for newcomers while strengthening the competitive advantage of dominant incumbents.

This dynamic reinforces the Innovation Winter: the more digital and data-dependent innovation becomes, the more obstacles accumulate in front of those attempting to build it.

Why These Barriers Matter — The Digital Innovation Trap

The combined effect of AI regulation, data governance restrictions, cybersecurity controls, and interoperability failures produces what researchers now call the Digital Innovation Trap:

The innovations that require the most data, the most transparency, and the most integration are the innovations the system is least capable of receiving.

In other words, the healthcare sector is structurally misaligned with the technologies most capable of improving patient outcomes, reducing costs, and transforming clinical workflows.

This misalignment deepens the Innovation Winter: the frontier of clinical progress moves further into digital, algorithmic, and connected technologies, while the system’s ability to evaluate, absorb, and deploy these technologies declines in parallel.

Rebuilding the Innovation Engine — A Scientific and Structural Blueprint

If the medical device sector is experiencing an Innovation Winter, then the central question becomes not simply why innovation is failing, but how a new system can be architected to reliably produce, support, and scale disruptive ideas. The solution cannot rely on exhorting corporations to “innovate more,” nor can it depend on isolated pockets of heroic clinician-inventors. What is required is a comprehensive re-alignment of regulation, reimbursement, procurement, data governance, clinical autonomy, incentive structures, and market design, such that the system becomes not merely permissive of innovation, but structurally conducive to it.

In essence, the industry must transition from a model based on centralised, corporation-driven incrementalism to one based on distributed, evidence-generating, clinically embedded innovation ecosystems. This requires deliberate policy construction, new institutional architecture, and a redefinition of how value is recognised, measured, funded, and rewarded.

Lean Clinical Evidence — Replacing the “All-or-Nothing” Burden with Iterative Evaluation

The traditional medical device paradigm assumes that promising technologies must generate large volumes of pre-market evidence before they can be used meaningfully in clinical practice. This model is no longer viable. Early-stage innovators cannot produce randomised data without access to clinical environments, clinicians cannot test prototypes without governance approval, and hospitals cannot approve pilots without reimbursement. The system is paralysed by a sequencing failure.

An innovation-driven framework requires iterative, risk-proportional evidence generation, beginning with:

target-trial emulation
small pragmatic pilots (20–50 patients)
observational comparative designs
in-clinic feasibility studies
registry anchoring for long-term outcomes

This is precisely the structure recommended in modern regulatory science (FDA RWE Framework), health-economic modelling guidelines, and methodological innovations such as adaptive designs and Bayesian evidence accumulation.

The goal is not to weaken evidence: it is to shift from pre-market proof to lifecycle demonstration, using real-world environments as the natural testbed for iteration.

Early HTA and Scientific Advice — Bringing Evaluators into the Innovation Process

Health Technology Assessment bodies increasingly determine market access, pricing, and adoption; however, their frameworks were historically optimised for pharmaceuticals, not rapidly iterating devices or AI systems. The result is a misalignment between the timing of innovation and the timing of evaluation.

A functional innovation engine requires synchronisation, achieved through early, structured dialogue such as:

NICE Scientific Advice (UK)
HAS Early Advice (France)
G-BA Innovationspool consultations (Germany)
RedETS early dialogue (Spain)
AGENAS & regional HTA scoping (Italy)

Early scientific advice allows innovators to:

design evidence that meets payer expectations
avoid infeasible endpoints
model economic value with realistic assumptions
ensure RWE pipelines map onto future HTA needs
reduce evidence waste

This creates regulatory coherence and economic predictability, both essential for attracting investment into disruptive technologies.

Real-World Economic Modelling — Moving Beyond the QALY Bottleneck

Traditional cost-effectiveness frameworks (CEA, CUA, ICER thresholds) are poorly suited to early-stage devices, especially those dependent on workflow redesign, organisational change, or cumulative marginal improvements. Early modelling must instead leverage cost-consequence analysis, time-to-event avoided, resource displacement, and failure-to-rescue metrics, which can be estimated with limited datasets and refined iteratively.

Moreover, real-world economic modelling should integrate:

micro-costing of procedural variation
hospital throughput impact
staffing requirements
training time
avoided complications
re-intervention prevention
learning-curve economics

This creates a dynamic valuation model, rather than the rigid frameworks that currently exclude disruptive devices from reimbursement consideration.

Hospital Innovation Sandboxes — Controlled Pathways for Safe Experimentation

Hospitals cannot become innovation engines unless they are structurally empowered to trial early-stage technologies without violating procurement rules or risk governance frameworks. The concept of an innovation sandbox, used effectively in fintech regulatory reform, is now essential in healthcare.

Such a sandbox would allow:

controlled, temporary regulatory flexibility
small-scale feasibility trials
limited procurement exemptions
clinician-led innovation partnerships
real-world data capture
cybersecurity-scoped environments
rapid iteration cycles

This reduces institutional fear, enables infrastructure readiness, and ensures early prototypes can be tested responsibly without navigating full procurement or reimbursement requirements.

Dormant IP Activation — Unlocking Unused Corporate Inventories

Multinational device companies maintain large intellectual property portfolios, many of which contain patents for products that were never developed, shelved due to market timing, or deprioritised after acquisition. This dormant IP represents an enormous, currently inaccessible pool of innovation potential.

A modern innovation engine requires:

structured IP release mechanisms
non-competitive licensing programmes
university partnerships
time-limited development rights
innovation fellowships enabling KOL-led refinement

This unlocks dormant assets without undermining corporate interests and allows disruptive ideas to be revitalised where clinical need and new evidence justify them.

Shared-Risk Reimbursement — Aligning Incentives Across Innovators and Payers

Outcomes-based reimbursement frameworks, widely used in pharmaceuticals, must now be applied to medical devices. This includes:

risk-sharing agreements
milestone-based payments
tariff adjustments conditional on real-world performance
savings-linked reimbursement
complication-reduction bonuses

These mechanisms align incentives so that:

innovators are rewarded for true clinical value
payers reduce uncertainty
hospitals adopt early-stage devices without financial risk

Shared-risk arrangements transform innovation from a speculative investment into a co-managed, evidence-driven partnership.

Cross-Sector Innovation Consortia — Building Distributed Creative Capacity

The future of MedTech innovation lies not in isolated corporate R&D labs but in distributed clinical–industrial consortia that combine:

clinicians
engineers
data scientists
regulatory experts
health economists
hospital IT teams
patient representatives

Such consortia accelerate:

prototype development
evidence generation
clinical feasibility
data governance harmonisation
AI model validation
regulatory navigation

Countries that master these collaborative ecosystems—like the Netherlands in diabetic technology, the Nordics in remote monitoring, and the U.S. in AI-enabled diagnostics—consistently outperform fragmented systems.

Policy Blueprint — Structural Reforms for the EU, UK, and U.S.

Fixing the MedTech innovation crisis requires coordinated structural reform, not isolated policies. The following blueprint draws on comparative analyses of international innovation frameworks, including the FDA Breakthrough Device Program, France’s Article 51 pilots, Germany’s §137e Innovation Funding, and the UK’s evolving MedTech Funding Mandate.

Early, Temporary, Conditional Reimbursement

Pioneered by France (Article 51) and increasingly mirrored elsewhere, early conditional reimbursement enables:

pilot deployment
preliminary evidence generation
real-world outcome tracking
economic data capture
rapid refinement

This single measure resolves the RWE–Reimbursement paradox for early innovators and dramatically accelerates the translation of disruptive technologies.

Regulatory Fast Lanes and Proportionality Principles

The EU must extend MDR with a proportional regulatory pathway for:

AI-enabled devices
low-risk digital tools
clinician-led innovations
early prototypes

Similarly, the UKCA framework and FDA’s Breakthrough Device pathway must be expanded to support smaller innovators, not only multinationals.

Procurement Reform — Rewarding Value, Not Volume

Governments should require:

innovation-weighted tender scoring
sandbox procurement exemptions
outcome-based contracting
diversified supplier portfolios
anti-concentration safeguards

This shifts procurement from a cost-minimising activity to a value-optimising mechanism that strengthens competition and accelerates innovation.

National Real-World Evidence Infrastructure

Countries must invest in:

interoperable registries
pseudonymised data hubs
device-level outcomes tracking
rapid-access ethical frameworks
patient safety observatories

This reduces startup evidence costs, increases HTA predictability, and supports lifecycle evaluation.

Workforce and Clinical-Enabler Policies

Reforms should include:

protected innovation time for clinicians
multidisciplinary innovation training
IP-sharing agreements with hospitals
clinician–engineer fellowship pathways
innovation-focused sabbaticals
academic credit for device development

Without clinician participation, the innovation engine cannot function at all.

Innovation Is Not an Event; It Is an Ecosystem

The decline of disruptive medical device innovation is not a moral failure, a lack of creativity, or a temporary fluctuation in corporate behaviour. It is the natural consequence of an ecosystem in which regulatory burdens, reimbursement structures, procurement practices, market concentration, digital constraints, and organisational psychology converge to suppress novelty and reward predictability.

If clinicians are the source of invention, innovators the source of risk-taking, corporations the source of scale, and health systems the source of patient need, then the innovation engine requires all four to operate in alignment. Today, they do not. They operate in tension, generating friction, inertia, and eventually stagnation.

Innovation cannot flourish when:

clinicians have no time to create;
hospitals cannot integrate new technologies;
regulators require evidence that cannot be generated;
payers reward stability over value;
corporations fear cannibalisation;
and early innovators face insurmountable barriers before their ideas take shape.

Rebuilding a functioning ecosystem requires acknowledging that innovation is not a product of individual genius but a structural output of systems designed to nurture, protect, and scale new ideas. If the system penalises risk, restricts data, imposes friction, concentrates power, and suppresses clinician creativity, then no amount of talent will offset these structural forces.

But with targeted reforms—in evidence generation, HTA alignment, reimbursement flexibility, procurement modernization, data infrastructure, and cross-sector collaboration—we can build an innovation engine capable of producing the next generation of transformative medical technologies. The potential is immense. What remains is the political, institutional, and economic will to build the system that innovation needs to survive.

References

Bergsland J, Elle OJ, Fosse E. Barriers to medical device innovation. Medical Devices: Evidence and Research (2014).
https://www.dovepress.com/barriers-to-medical-device-innovation-peer-reviewed-fulltext-article-MDER

Jarosławski S, Saberwal G. Case studies of innovative medical device companies: barriers and enablers. BMC Health Services Research (2013).
https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-13-199

Courvoisier A. The future of academic innovation in medical devices. Expert Review of Medical Devices (2016).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074480/

Maresova P et al. New medical device regulations in Europe. Administrative Sciences (2020).
https://www.mdpi.com/2076-3387/10/1/16

Maresova P et al. Potential of the medical device industry. Therapeutics and Clinical Risk Management (2015).
https://www.dovepress.com/the-potential-of-medical-device-industry-in-technological-and-economic-peer-reviewed-fulltext-article-TCRM

Zippel C, Bohnet-Joschko S. Post-market surveillance and innovation. Therapeutic Innovation & Regulatory Science (2017).
https://journals.sagepub.com/doi/full/10.1177/2168479016664077

Van der Panne G et al. Success and failure of innovation.
https://core.ac.uk/download/pdf/36024515.pdf

Vollmer S et al. Machine learning for patient benefit. BMJ (2020).
https://www.bmj.com/content/368/bmj.m689

Price WN, Cohen IG. Privacy in medical big data. Nature Medicine (2019).
https://www.nature.com/articles/s41591-018-0272-7

Pinheiro P. Connectivity and avoiding innovation deadlock.
https://www.med-technews.com/features/medicaldevices-connectivity-and-avoiding-innovation-deadloc/

Akpinar I et al. Cost of medical device trials. PharmacoEconomics Open (2019).
https://link.springer.com/article/10.1007/s41669-018-0079-4

Horvath J. Empirically assessing medical device innovation.
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4824122

How to build an Innovation Engine: